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Summan Previous cross-sectional data suggest a positive association between serum cholesterol and brain
neoplasms. but the results of cohort studies are inconclusive. There is evidence that in women the growth of
meningiomas and astrocytomas depends on the hormonal status. The present investigation comprised data on
serum cholesterol and P-lipoprotein concentration among 229 participants in a health survey with subsequently
diagnosed central nervous system (CNS) tumours. Data analyses included comparison of mean serum
cholesterol and P-lipoprotein level between cases and randomly selected controls - five for each case. matched
for sex. age at screening and time of examination. The results showed a positive relation between the
A-lipoprotein level and the development of a CNS tumour (benign or malignant) in women under 50 years of
age. and a negative association in those of older age with development of malignant tumours. which implies a
possible influence of the menopausal status. Repeating the computations after excluding cases diagnosed
within 5 vears from screening revealed significant associations also between the serum cholesterol concentra-
tion and the development of a malignant CNS tumour, with a pattern similar to that of frlipoprotein. In
conclusion, in women. irregular variation in the P-lipoprotein level. which is involved in the synthesis of
progesterone in the CNS. may enhance oncogenic transformation of astrocytes and meningeal cells: however.
transformation of the latter is restricted to vounger women.
Case-control studies suggest a positive association between
serum cholesterol concentration and brain neoplasms (Basu
et al.. 1974: Abramson & Kark. 1985: Neugut et al.. 1989).
but the results of cohort studies are inconclusive (Davey
Smith & Shipley. 1989: Knekt et al.. 1991: Davey Smith et
al.. 1992). In the Whitehall study a positive relation between
plasma cholesterol and mortality from brain cancer was
found among men (Davey Smith & Shipley. 1989). The latest
and largest study so far included 399 deaths from central
nervous system (CNS) neoplasms among the participants in
the male screening Multiple Risk Factor Intervention Trial
(Davey Smith et al.. 1992). No significant association was
found. However. according to one of the case-control
studies. the difference in serum cholesterol concentration
between subjects with and without brain tumours was
significant only among women (Neugut et al., 1989).
As there is evidence that in women the growth of such
brain tumours as meningiomas and astrocytomas depends on
the hormonal status (Schipper. 1986: Roelvink et al.. 1987).
the aim of the present study was to examine the association
of benign as well as of malignant CNS tumours with both
serum cholesterol and frlipoprotein concentration in men
and women. with special emphasis on evaluating the effect of
menopausal status on these relations.
Subjects and methods
In 1962-65. 97.468 persons from four Mid-Swedish geo-
graphical districts took part in a general health survey con-
ducted among the total population of these areas aged 25
years or older. The participation rate was 77.0%. Details of
the recruitment and screening methods used have been given
elsewhere (Lindberg et al.. 1991).
Briefly. the screening examination included measurement
of weight. height and laboratory determination of different
parameters. Body mass index was calculated as weight (kg)
height(m-). All serum analyses were run on the same auto-
matic multiple analyser (AutoChemist). Cholesterol was
analysed by the Liebermann-Burchard method (Zak et al..
1954) and -lipoprotein according to the method of Burstein
and Samaille (1959). Total serum cholesterol values expressed
in mg dl-' were recalculated to mmol 1-P' by multiplication by
0.02586. The frlipoprotein values. originally measured in
units, were converted to g 1' using a multiplication factor of
0.18 (Burstein & Samaille. 1959).
For each participant additional information on the socio-
economic status was collected. based on the 1960 national
census including 12 socioeconomic groups.
In accordance with a previously used design. survey data
were matched with the National Cancer Register in order to
identify all new cases of a CNS tumour in the study popula-
tion during the period 1962 to 1985 (Gatchev et al.. 1993). A
CNS tumour was classified as any brain or intraspinal neo-
plasm including those of the meninges. Of all cancers diag-
nosed in Sweden approximately 96% are reported to the
cancer register. but for the cases with histologically confirmed
diagnosis this proportion is 98%. The present study did not
include cases without histological categorisation of the diag-
nosis and with tumours notified before the health examina-
tion. Cases were classified into two groups - those with
benign or malignant CNS tumours. depending on the histo-
logical diagnosis (Table I). As is evident from data that
appear elsewhere (Gatchev et al.. 1993), of 296 identified
cases with a CNS tumour. 48 (16%) lacked histological
diagnosis and 19 (6%) were notified to the cancer register
before the health examination. These cases were excluded. Of
the remaining 229 cases, 1 8 (52%) were men and 11 1 (480%)
women. As seen in Table I. 124 (54%) of the tumours were
benign and 105 (46%) were malignant. The proportion of
malignant tumours was higher in men than in women. 66
(56%) compared with 39 (35%). Of the malignant neop-
lasms. 97 (92%0) were astrocytomas grade III-IV. with
similar proportions in men (62. 94%) and women (35. 900 o).
Astrocytoma grade I-II and meningioma were the most
common benign CNS tumours (82%): 41 (79%) occurred in
men and 60 (83%) in women.
Using a nested case-control design. for each case five
controls (590 men and 555 women) were randomly selected
from the whole study population. They were matched for
sex, age at screening (5 year groups) and time (year and
month) of serum cholesterol and frlipoprotein determination.
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Table I Number (%0) of CNS tumours by histological diagnosis (Gatchev et al.. 1993)
Benign CNS tumours No. (% Malignant CNS tunours No. (%
Astrocvtoma grade 1-IIA 31 (25) Astrocytoma grade III-IVa 97 (92)
Meningioma 70 (57) Malignant meningioma 1 (1)
Neunrnoma 15 (12) Malignant neurinoma 4 (4)
Ependymoma 1 (<1) Malignant ependymoma 1 (1)
Plexus papilloma 2 (2) Neuroblastoma 1 (1)
Craniopharyngioma 2 (2) Suspect malignant glioma 1 (1)
Haemangioma 3 (2)
Total 124 (100) Total 105 (100)
dAstrocvtomas have been graded histologicallv acording to the criteria of Kernohan et al.
(1949).
the last to neutralise the influence of possible laboratory
drift.
Statistical methods
Analysis of variance (ANOVA) was used to examine differ-
ences in mean serum cholesterol and P-lipoprotein concentra-
tion between the matched cases and controls with adjustment
for socioeconomic status and body mass index. The 95%
confidence intervals for differences were calculated using a
matched design. In order to investigate the possible effect of
menopausal status on the studied relationships, women were
stratified into two subgroups. The first group included those
who were <50 years both at screening and at tumour diag-
nosis and the second were all > 50 years of age at these
occasions. Those subjects who participated in the health
survey before the age of 50 years and had a CNS tumour
diagnosed after that age were excluded from the subgroup
analysis. For comparison. the same analyses were also per-
formed among men. Statistical significance was assumed at
P<0.05. All tests were two-sided.
Results
For the patients with benign CNS tumours mean (± s.d.) age
at diagnosis did not differ between men (59 ± 13 years) and
women (59 ± 12 years). The malignant tumours were diag-
nosed at a mean age of 58 ± 10 years in men and 60 ± 9
years in women. but this difference was not statistically
significant (P = 0.3).
Neither in men nor in women were any statistically
significant differences found in the mean serum cholesterol
concentration between cases and controls (Table II). The
same was true for P-lipoprotein.
No statistically significant differences were seen in total
cholesterol level between cases and controls after separation
of the women by age (Table III). As is further seen in the
table, the A-lipoprotein level in cases with a malignant CNS
neoplasm differed significantly from that in both younger
(<50 years) and older controls (. 50 years). The difference
was, however, not consistent, as in women <50 years the
P-lipoprotein level was significantly higher, which was also
true for cases with a benign CNS tumour. For cases aged 50
years and older, however, this concentration was lower
among those with a malignant tumour.
Analyses were repeated after exclusion of subjects with
tumour diagnosed during the first 5 years after screening and
their corresponding controls. Among malignant female cases
the difference in mean serum cholesterol concentration
between cases and controls became statistically significant in
Tablen Mean (standarddeviation) serum cholesterol andfrlipoprotein
concentration at screening among cases with benign or with malignant
CNS tumour compared with corresponding matched controls
Serun cholesterol P-Lipoprotein
concentration concentration
Groups No. (mmol 1- la {g 1- / )
AUen
Benign CNS tumours 52 6.4 (1.2) 2.2 (0.6)
Controls 260 6.5 (1.1) 2.2 (0.5)
Malignant CNS tumours 66 6.5 (1.0) 2.2 (0.7)
Controls 330 6.5 (1.0) 2.1 (0.5)
Women
Benign CNS tumours 72 6.5 (1.0) 2.2 (0.7)
Controls 360 6.7 (1.0) 2.2 (0.6)
Malignant CNS tumours 39 6.8 (1.3) 2.3 (0.7)
Controls 195 6.7 (1.0) 2.2 (0.6)
aOriginal values given in mg dl are converted to mmol 1-' by a
factor of0.02586. 'Original values given in units are converted to g 1-'
by a factor of 0.18 (Burstein et al.. 1959).
Table III Mean (standard deviation) serum cholesterol and S-lipoprotein concentration at screening among women <50 or > 50 sears of
age by CNS tumour groups before and after excluding cases with tumour notification within 5 years from screening. compared with
corresponding matched controls and mean difference in cases and controls with 95% confidence intervals (CI)
Serum cholesterol concentration (mmoll-1) frlipoprotein concentration (g l-I
Groups No. <50 years No. ) 50 -iears <5O ears ) 50 years
Before exclusion
Benign CNS tumours 17 6.3 (0.9) 35 6.7 (1.1) 2.3 (0.6) 2.2 (0.7)
Controls 85 6.4 (0.9) 175 6.9 (1.0) 1.9 (0.5) 2.3 (0.7)
Mean difference (950,'* Cl) -0.1 (-0.53. 0.39) -0.2 (-0.56. 0.16) 0.4 (0.10. 0.58) -0.1 (-0.33. 0.13)
Malignant CNS tumours 6 7.1 (1.5) 16 6.6 (1.1) 2.4 (0.5) 2.0 (0.5)
Controls 30 6.3 (0.6) 80 7.1 (1.0) 1.8 (0.4) 2.4 (0.6)
Mean difference (95° O CI) 0.8 (-0.18. 1.64) -0.5 (-1.01. 0.03) 0.6 (0.26. 0.90) -0.4 (-0.66. -0.14)
After exclusion
Benign CNS tumours 8 6.3 (0.6) 24 6.7 (1.2) 2.3 (0.7) 2.3 (0.8)
Controls 40 6.4 (0.8) 120 6.8 (0.9) 2.0 (0.5) 2.3 (0.6)
Mean difference (95O Cl) -0.1 (-0.65. 0.53) -0.1 (-0.53. 0.31) 0.3 (-0.08. 0.72) 0 (-0.27. 0.25)
Malignant CNS tumours 5 7.2 (1.6) 10 6.0 (0.7) 2.4 (0.6) 2.1 (0.6)
Controls 25 6.2 (0.8) 50 7.0 (1.0) 1.9 (0.4) 2.5 (0.6)
Mean difference (95%o CI) 1.0 (0.12. 1.90) -1.0 (-1.67. -0.39) 0.5 (0.13. 0.87) -0.4 (-0.77. -0.07)670 0. GATCHEV et al.
both subgroups with a pattern similar to that of P-lipo-
protein. For younger women with a benign CNS tumour, the
difference in frlipoprotein level was no longer significant
(P = 0.13).
No corresponding findings were observed in men, and
none of the above results were influenced by repeating the
statistical tests after adjustment for socioeconomic status and
body mass index.
Di%cssio
It is suggested that the central nervous system has a mechan-
ism of cholesterol transport and supply, connected with the
system for cholesterol homeostasis in the rest of the body
(Pitas et al.. 1987; Meresse et al., 1989). Brain cells utilise
cholesterol derived either from serum, after its transfer across
the blood-brain barrier, or from endogenous (de novo) syn-
thesis in the brain (Pitas et al., 1987; Meresse et al., 1989).
Apolipoprotein E-containing HDL-like lipoproteins play an
important role in cholesterol redistribution within the CNS
(Pitas et al.. 1987). These lipoproteins most likely interact
with special receptors of the recipient cells - the apolipo-
protein B and E (LDL) receptors, which results in cellular
uptake and breakdown of the lipoprotein particle (Brown &
Goldstein, 1976). Such receptors have been found in the CNS
of several animals, and also in pial cells of the arachnoid and
in adjacent astrocytes of monkey brain (Pitas et al., 1987),
but are probably also present in the corresponding human
cells. However, in steroidogenic cells, which utilise mainly
cholesterol of exogenous origin, an alternative mechanism for
cholesterol delivery may also exist (Gwynne & Strauss,
1982).
The present study showed a positive association between
the P-lipoprotein level measured at screening and the
development of a CNS tumour (benign or malignant) in
women under the age of 50 years, while among older women
a negative relation was identified for malignant but not for
benign tumour cases.
P-Lipoprotein (an approximate measure of LDL) may parti-
cipate in cholesterol transport through the blood-brain bar-
rier, in this way affecting the cholesterol supply to the CNS.
This is supported by the fact that even slight changes in the
serum cholesterol level correlate with the receptor-dependent
LDL uptake in the CNS (Malavotti et al., 1991), and by the
existence of apolipoprotein B and E (LDL) receptors on the
endothelial cells of brain capillaries (Meresse et al., 1989).
Cholesterol is the main substrate for synthesis of sex hor-
mones, which have a regulative effect upon brain cells, by
both genomic and non-genomic mechanisms, the latter being
expressed via direct binding to membrane receptors of the
target cells (McEwen, 1991). Normal brain tissue has recep-
tors for all steroid hormones scattered among different struc-
tures and cell types. including those of the meninges
(McEwen et al., 1982; Poisson et al., 1983). Several inves-
tigators have reported on the existence of both progesterone
and oestrogen receptors in meningiomas and gliomas,
explaining it as evidence of possible hormonal sensitivity of
the tumours (Poisson et al., 1984; Riva et al., 1990).
Sex steroids found in the CNS originate from both extra-
and intracerebral synthesis, but only the latter has been
proven for progesterone and its precursors (Baulieu & Robel,
1990). Astrocytes metabolise progesterone, converting it to
various neuroendocrinologically active derivatives, which can
interact with the progesterone receptors (Karavolas &
Hodges, 1990). In glial cells the regulative steroid effects
could lead to alterations in the hormonal sensitivity and
metabolism (McEwen et al., 1982), and endocrine modula-
tion of brain functions may also play a role for the occur-
rence of disease (McEwen et al., 1991).
The opposite direction of the associations between P-lipo-
protein level and development of a CNS tumour in young
and old women (separated to assess the impact of meno-
pausal status) implies such an effect. Sex hormones from
both extra- and intracerebral synthesis in the brain are
involved. The latter source contributes greatly to the high
brain levels of progesterone and of its active compounds,
which by far exceed the corresponding concentrations in
plasma (McEwen, 1992).
One plausible explanation of the dissimilarities between the
analysed subgroups could be that differences in -lipoprotein
levels are associated with differences in progesterone syn-
thesis in the CNS. This should be limited exclusively to the
glial cells, where production and metabolism of progesterone
is taking place (Baulieu & Robel, 1990). One could raise the
hypothesis that the abnormal steroid regulation at genomic
level, induced by the above alterations, is related to onco-
genic transformation in the astrocytes. Certainly, steroids of
peripheral origin also may participate in this process (Back-
str6m, 1990). Therefore, in this summary, it is possible that
differences in progesterone homeostasis, related to the P-
lipoprotein level, will further contribute to the already higher
brain progesterone level among premenopausal women, and
to a decrease of the normally lower progesterone concentra-
tion after menopause. The consequence would in both cases
be changes in the intracellular progesterone modulation with
increased risk of neoplastic transformation.
The involvement of the meningeal cells (benign tumours)
was, however, limited to women under the age of 50 years.
This might be related to increased progesterone uptake by
these cells, owing to its more intensive transfer from adjacent
glial compartments, where the progesterone level is high. The
reported occurrence of a high oestrogen level in the brain of
fertile women (Bixo, 1987) could also be of some importance
in this respect, because oestrogen can regulate the synthesis
of progesterone receptors (McEwen, 1991), and may in this
way influence the progesterone cell uptake.
Five years is a reasonable period for exclusion of tumour
cases to avoid a preclinical impact on the levels ofthe studied
parameters (Sherwin et al., 1987). Repeating the analyses
after this procedure revealed in both studied subgroups
among women statistically significant associations between
the total serum cholesterol concentration and the develop-
ment of a malignant CNS tumour, with the same direction as
corresponding P-lipoprotein levels. Alterations in the statis-
tical significance regarding the importance of the P-lipo-
protein concentration are most probably due to weakened
statistical power as a result of the reduced number of
analysed subjects.
Adjustment for socioeconomic status, which is a factor
that is related to the serum cholesterol level, was performed
in all of the previous cohort studies (Davey Smith & Shipley,
1989; Knekt et al., 1991; Davey Smith et al., 1992), and in
two of them (Davey Smith & Shipley, 1989; Knekt et al.,
1991) also for body mass index. As in the present investiga-
tion, this did not have any impact on the results.
Misclassification of studied astrocytomas owing to histo-
logical sampling error would weaken the statistical
significance of observed differences between cases and cont-
rols. Hence, the observed results occurred despite possible
misclassifications and not because of them.
In conclusion, in women, irregular variation in the P-
lipoprotein level, which is involved in the synthesis of pro-
gesterone in the CNS, may enhance oncogenic transforma-
tion of astrocytes in women of all ages and of meningeal cells
in younger women only.
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